1-(2-Methyl-1,3-dithian-2-yl)-2,3-dihydroinden-1-ol | 936231-47-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 1-(2-Methyl-1,3-dithian-2-yl)-2,3-dihydroinden-1-ol
• CAS: 936231-47-9
• 化学式: C₁₄H₁₈OS₂
• 分子量: 266.428
• InChiKey: WJTAUZZVAAIWIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  70.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-Methyl-1,3-dithian-2-yl)-2,3-dihydroinden-1-ol 在 甲醇 、 mercury(II) perchlorate 、 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 生成 Methyl 4'-oxospiro[1,2-dihydroindene-3,5'-furan]-2'-carboxylate
  参考文献：
  名称：

  Analogues of Acifran:  Agonists of the High and Low Affinity Niacin Receptors, GPR109a and GPR109b

  摘要：

  Recently identified GPCRs, GPR109a and GPR109b, the high and low affinity receptors for niacin, may represent good targets for the development of HDL elevating drugs for the treatment of atherosclerosis. Acifran, an agonist of both receptors, has been tested in human subjects, yet until recently very few analogs had been reported. We describe a series of acifran analogs prepared using newly developed synthetic pathways and evaluated as agonists for GPR109a and GPR109b, resulting in identification of compounds with improved activity at these receptors.

  DOI：

  10.1021/jm070022x
• 作为产物：
  描述：

  2-甲基-1,3-二噻烷 、 1-茚酮 在 正丁基锂 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 生成 1-(2-Methyl-1,3-dithian-2-yl)-2,3-dihydroinden-1-ol
  参考文献：
  名称：

  Analogues of Acifran:  Agonists of the High and Low Affinity Niacin Receptors, GPR109a and GPR109b

  摘要：

  Recently identified GPCRs, GPR109a and GPR109b, the high and low affinity receptors for niacin, may represent good targets for the development of HDL elevating drugs for the treatment of atherosclerosis. Acifran, an agonist of both receptors, has been tested in human subjects, yet until recently very few analogs had been reported. We describe a series of acifran analogs prepared using newly developed synthetic pathways and evaluated as agonists for GPR109a and GPR109b, resulting in identification of compounds with improved activity at these receptors.

  DOI：

  10.1021/jm070022x